Comprehensive Market Report: Global Familial Adenomatous Polyposis (FAP) Therapeutics and Management Market
Executive Summary
The global Familial Adenomatous Polyposis (FAP) Therapeutics and Management market is a highly specialized, niche segment within the rare disease and gastrointestinal oncology landscape. FAP is a rare, inherited disorder characterized by the development of hundreds to thousands of colorectal polyps with a near 100% risk of progressing to colorectal cancer if untreated. The market, focused on both chemoprevention and post-surgical management, was valued at an estimated USD XX million in 2025 and is projected to reach USD YY million by 2036, growing at a significant Compound Annual Growth Rate (CAGR) of Z% from 2026 to 2036. This growth is driven by the high unmet medical need for effective, non-surgical therapies, increasing genetic screening and diagnosis, and the anticipated launch of novel, disease-modifying agents. This report provides a strategic analysis of the evolving treatment paradigm, competitive pipeline, and key market access dynamics.
1. Segments Analysis
By Treatment Modality & Approach:
-
Surgical Intervention (Current Standard of Care):
-
Prophylactic Colectomy: Total or subtotal colectomy, often with ileorectal anastomosis (IRA) or restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). This is the definitive, curative-intent procedure but carries significant morbidity and quality-of-life impacts.
-
Endoscopic Polypectomy: For management of duodenal/ampullary polyps or rectal stump surveillance post-colectomy.
-
-
Chemopreventive Pharmacotherapy (Key Growth Segment):
-
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Established off-label use (e.g., Sulindac, Celecoxib). Act as the historical benchmark for polyp regression but are limited by cardiovascular/renal side effects and lack of FDA approval for FAP.
-
Novel, Targeted Chemoprevention Agents: The focus of clinical development. Includes:
-
Eflornithine + Sulindac Combination (CPP-1X/sul): A leading investigational combination with Phase III data showing significant efficacy in delaying disease progression.
-
Other Novel Mechanisms: Agents targeting Wnt/β-catenin pathway (dysregulated in FAP), COX-2 inhibitors, and other molecular targets.
-
-
-
Supportive & Symptomatic Care: Includes nutritional support, pain management, and treatment of extra-colonic manifestations (desmoid tumors, osteomas, CHRPE).
By Patient Population & Disease Stage:
-
At-Risk & Pre-Prophylactic Colectomy Patients: The primary target for chemoprevention to delay or avoid surgery.
-
Post-Colectomy Patients (with IRA): Patients with retained rectum requiring lifelong surveillance and management of rectal polyps. A key population for chemoprevention to prevent proctectomy.
-
Patients with Desmoid Tumors (Aggressive Fibromatosis): A severe extra-colonic manifestation requiring specialized treatment (e.g., tyrosine kinase inhibitors, chemotherapy).
By Distribution Channel:
-
Hospital Pharmacies (Specialty Dispensing): For inpatient surgical care and infusion therapies.
-
Specialty Pharmacies & Mail-Order: For dispensing high-cost, orphan-designated oral chemopreventive drugs.
-
Retail Pharmacies: For generic NSAIDs and supportive medications.
2. Key Players
The market involves innovative biotechnology firms, specialty pharma, and large pharma with orphan/oncology divisions. Surgical care is decentralized.
Leading Companies (Therapeutics Focus):
-
Cancer Prevention Pharmaceuticals, Inc. (CPP) - (Lead asset: Eflornithine + Sulindac [CPP-1X/sul])
-
Pfizer Inc. - (Historical role with Celebrex®/celecoxib; interest in oncology)
-
Ionis Pharmaceuticals, Inc. - (Antisense oligonucleotide platform for rare diseases)
-
Thetis Pharmaceuticals LLC - (TPI-2154, a novel chemoprevention agent)
-
Recursion Pharmaceuticals - (AI-driven drug discovery for rare diseases like FAP)
-
SpringWorks Therapeutics, Inc. - (Focus on rare tumors, including desmoid tumors common in FAP)
-
Deciphera Pharmaceuticals, Inc. - (QINLOCK®/ripretinib for desmoid tumors)
-
Bayer AG - (Nexavar®/sorafenib used off-label for desmoid tumors)
-
F. Hoffmann-La Roche Ltd - (Through its oncology and diagnostics divisions)
-
Guardant Health, Inc. - (Liquid biopsy for monitoring and early detection in high-risk patients)
3. Regional Analysis
-
North America: The largest and most advanced market. Driven by high diagnosis rates via genetic counseling, a robust clinical trial infrastructure, favorable orphan drug policies, and the anticipated first approval of novel agents (e.g., CPP-1X/sul) in the US.
-
Europe: A significant market with strong rare disease frameworks. Growth is supported by centralized healthcare systems, established patient registries, and EMA orphan drug designation pathways. Germany, UK, and France are key markets.
-
Asia-Pacific: An emerging market with growing awareness. Japan has advanced genetic medicine and will be a key launch market. Growth in China and Australia is tied to improving genetic diagnostics and rare disease recognition.
-
Latin America, Middle East & Africa: Limited markets with significant access barriers. Care is concentrated in major academic centers. Growth is slow and dependent on patient assistance programs and improving genetic testing infrastructure.
4. Porter’s Five Forces Analysis
-
Competitive Rivalry (Low to Moderate, but Emerging): Currently low with no approved dedicated pharmacotherapy. Rivalry will intensify with the first FDA/EMA approval, as companies compete on efficacy, safety, and convenience data. Surgical care is non-competitive from a market perspective.
-
Bargaining Power of Suppliers (Low): API manufacturers and CMOs for small molecule drugs are numerous. For novel biologics or complex formulations, supplier power may be moderate.
-
Bargaining Power of Buyers (Very High): Buyers are a small, concentrated group of payers (government agencies, specialized insurers) and a tiny, well-organized patient population. Given the ultra-orphan nature and expected high price, payers will demand exceptional outcomes data for reimbursement.
-
Threat of New Entrants (Moderate for Biotech): Scientific barriers are high due to complex disease biology. However, the orphan drug status with incentives (market exclusivity, tax credits) attracts biotech investment. Large pharma may enter via acquisition of successful Phase II/III assets.
-
Threat of Substitutes (High - Surgery): Prophylactic surgery is a definitive, one-time substitute for pharmacotherapy in preventing colorectal cancer. The value proposition of drugs is to delay or avoid surgery, competing on quality of life and morbidity. This is the central market dynamic.
5. SWOT Analysis
-
Strengths: Addresses a severe unmet need with high disease burden; benefits from orphan drug designations (7-year US exclusivity, 10-year EU); potential for high pricing if transformative efficacy is proven; strong patient advocacy support.
-
Weaknesses: Extremely small patient population (~1 in 10,000); challenging clinical trials due to rarity and slow polyp progression; risk of side effects from long-term preventive drug use; need for lifelong adherence.
-
Opportunities: First-to-market advantage for a dedicated FAP therapy; expansion into related syndromes (e.g., MUTYH-associated polyposis); development of companion diagnostics for patient stratification; demonstration of pharmacoeconomic value by reducing surgical burden.
-
Threats: Clinical trial failures remain a significant risk; payer resistance to high-cost chronic therapy for a "preventive" indication in a rare disease; potential for generic NSAIDs to be used as a low-cost comparator, limiting pricing power.
6. Trend Analysis, Drivers & Challenges
Key Trends:
-
Shift from Reactive Surgery to Proactive Pharmacoprevention: The core paradigm shift driving the market. Moving from inevitable colectomy to medical management to delay or modify disease course.
-
Combination Therapy Approach: Recognition that single agents may be insufficient; combining drugs with complementary mechanisms (e.g., CPP-1X/sul) is the leading strategy.
-
Biomarker-Driven Development & Monitoring: Use of genetic markers (APC mutation), polyp burden on endoscopy, and emerging liquid biopsy to stratify patients and measure treatment response.
-
Integrated, Multidisciplinary Care Models: Coordination between clinical geneticists, gastroenterologists, surgeons, and oncologists for holistic patient management.
Primary Drivers:
-
High Unmet Medical Need & Desire to Avoid Surgery: The profound impact of colectomy on quality of life creates a powerful demand for effective non-surgical options.
-
Improving Genetic Diagnosis & Screening: Increased use of cascade genetic testing in families identifies at-risk individuals earlier, expanding the treatable population pre-surgery.
-
Orphan Drug Incentives: Attract R&D investment into this small but critical patient population.
-
Positive Late-Stage Clinical Data: Readouts from pivotal trials (e.g., CPP's trial) validating chemoprevention efficacy.
Critical Challenges:
-
Ultra-Orphan Population & Recruitment: Difficulty in enrolling sufficient patients for statistically powered clinical trials.
-
Defining Clinically Meaningful Endpoints: Regulatory agreement on surrogate endpoints (e.g., polyp number/size regression) versus long-term cancer prevention is complex.
-
Reimbursement & Market Access: Justifying premium pricing to payers for a chronic preventive therapy, despite the high cost of avoided surgeries and cancers.
-
Long-Term Safety Data: Requirement for extensive post-marketing surveillance to monitor rare side effects of lifelong therapy.
7. Value Chain Analysis
-
Basic Research & Target Discovery: Understanding APC gene function and Wnt pathway biology in academic and biotech settings.
-
Drug Discovery & Preclinical Development: Screening and optimizing candidate compounds.
-
Clinical Development (Phases I-III): The most critical and costly phase, conducted in a network of specialized FAP centers worldwide.
-
Regulatory Strategy & Orphan Drug Designation: Navigating FDA/EMA with natural history data and novel endpoints.
-
Commercial Manufacturing & Supply Chain: For an ultra-orphan drug, manufacturing scale is small but must be reliable.
-
Pricing, Reimbursement & Market Access: The ultimate commercial gatekeeper. Requires extensive health economic outcomes research (HEOR) to demonstrate value.
-
Distribution & Patient Support: Through specialty pharmacies coupled with comprehensive patient support programs (navigators, financial assistance, adherence support).
-
Clinical Care & Monitoring: Prescription by specialist gastroenterologists and ongoing endoscopic surveillance.
Maximum value is concentrated in successful late-stage clinical development and the subsequent ability to secure premium pricing and broad reimbursement based on transformative clinical data.
8. Quick Recommendations for Stakeholders
-
For Biotechnology Innovators (CPP, Thetis): Secure regulatory approval based on robust, agreed-upon endpoints. Post-approval, immediately invest in health economics and outcomes research (HEOR) to build an incontrovertible case for payer reimbursement. Develop strong patient advocacy partnerships to ensure education and access. Plan for lifecycle management (new formulations, pediatric studies).
-
For Large Pharmaceutical Companies: Act as a commercial partner or acquirer for successful late-stage assets. Provide global regulatory and market access expertise. Your existing oncology and rare disease commercial infrastructure can be leveraged for efficient launch. Explore in-licensing of complementary diagnostic tools.
-
For Payers & HTA Bodies: Develop innovative reimbursement models for ultra-orphan preventive therapies, such as outcomes-based agreements linked to reduced surgical interventions or cancer incidence. Engage with manufacturers early in the development process to align on evidence needs.
-
For Healthcare Providers (Gastroenterologists, Geneticists): Standardize genetic testing and surveillance protocols to identify patients earlier. Participate in clinical registries to contribute to natural history data. Upon launch of new therapies, develop clear patient selection criteria for chemoprevention versus continued surveillance or surgery.
-
For Investors: This is a high-risk, high-reward, binary investment tied to clinical trial success. Focus on companies with strong Phase III data in hand or imminent. The key value inflection is regulatory approval and subsequent positive reimbursement decisions. Diversify across companies targeting different mechanisms within the FAP space.
Report Basis: History Years: 2020-2024; Base Year: 2025; Forecast Period: 2026-2036.
Note: All market values (XX, YY) and CAGR (Z%) are illustrative placeholders. This is a forward-looking analysis of a pre-commercial, pipeline-driven orphan disease market. Customized data, including probability-adjusted revenue forecasting, detailed pipeline analysis, and patient-based demand modeling, is available per client specifications.
Table of Contents
Global Familial Adenomatous Polyposis Treatment Sales Market Report 2018
1 Familial Adenomatous Polyposis Treatment Market Overview
1.1 Product Overview and Scope of Familial Adenomatous Polyposis Treatment
1.2 Classification of Familial Adenomatous Polyposis Treatment by Product Category
1.2.1 Global Familial Adenomatous Polyposis Treatment Market Size (Sales) Comparison by Type
1.2.2 Global Familial Adenomatous Polyposis Treatment Market Size (Sales) Market Share by Type (Product Category) in
1.2.3 Icosapent
1.2.4 Eflornithine Hydrochloride
1.2.5 Aspirin
1.2.6 CEQ-508
1.2.7 Others
1.3 Global Familial Adenomatous Polyposis Treatment Market by Application/End Users
1.3.1 Global Familial Adenomatous Polyposis Treatment Sales (Volume) and Market Share Comparison by Application
1.3.1 Clinic
1.3.2 Hospital
1.3.3 Others
1.4 Global Familial Adenomatous Polyposis Treatment Market by Region
1.4.1 Global Familial Adenomatous Polyposis Treatment Market Size (Value) Comparison by Region
1.4.2 United States Familial Adenomatous Polyposis Treatment Status and Prospect
1.4.3 Europe Familial Adenomatous Polyposis Treatment Status and Prospect
1.4.4 China Familial Adenomatous Polyposis Treatment Status and Prospect
1.4.5 Japan Familial Adenomatous Polyposis Treatment Status and Prospect
1.4.6 Southeast Asia Familial Adenomatous Polyposis Treatment Status and Prospect
1.4.7 India Familial Adenomatous Polyposis Treatment Status and Prospect
1.5 Global Market Size (Value and Volume) of Familial Adenomatous Polyposis Treatment
1.5.1 Global Familial Adenomatous Polyposis Treatment Sales and Growth Rate
1.5.2 Global Familial Adenomatous Polyposis Treatment Revenue and Growth Rate
2 Global Familial Adenomatous Polyposis Treatment Competition by Players/Suppliers, Type and Application
2.1 Global Familial Adenomatous Polyposis Treatment Market Competition by Players/Suppliers
2.1.1 Global Familial Adenomatous Polyposis Treatment Sales and Market Share of Key Players/Suppliers ()
2.1.2 Global Familial Adenomatous Polyposis Treatment Revenue and Share by Players/Suppliers ()
2.2 Global Familial Adenomatous Polyposis Treatment (Volume and Value) by Type
2.2.1 Global Familial Adenomatous Polyposis Treatment Sales and Market Share by Type ()
2.2.2 Global Familial Adenomatous Polyposis Treatment Revenue and Market Share by Type ()
2.3 Global Familial Adenomatous Polyposis Treatment (Volume and Value) by Region
2.3.1 Global Familial Adenomatous Polyposis Treatment Sales and Market Share by Region ()
2.3.2 Global Familial Adenomatous Polyposis Treatment Revenue and Market Share by Region ()
2.4 Global Familial Adenomatous Polyposis Treatment (Volume) by Application
3 United States Familial Adenomatous Polyposis Treatment (Volume, Value and Sales Price)
3.1 United States Familial Adenomatous Polyposis Treatment Sales and Value ()
3.1.1 United States Familial Adenomatous Polyposis Treatment Sales and Growth Rate ()
3.1.2 United States Familial Adenomatous Polyposis Treatment Revenue and Growth Rate ()
3.1.3 United States Familial Adenomatous Polyposis Treatment Sales Price Trend ()
3.2 United States Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Players ()
3.3 United States Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Type ()
3.4 United States Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Application ()
4 Europe Familial Adenomatous Polyposis Treatment (Volume, Value and Sales Price)
4.1 Europe Familial Adenomatous Polyposis Treatment Sales and Value ()
4.1.1 Europe Familial Adenomatous Polyposis Treatment Sales and Growth Rate ()
4.1.2 Europe Familial Adenomatous Polyposis Treatment Revenue and Growth Rate ()
4.1.3 Europe Familial Adenomatous Polyposis Treatment Sales Price Trend ()
4.2 Europe Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Players ()
4.3 Europe Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Type ()
4.4 Europe Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Application ()
5 China Familial Adenomatous Polyposis Treatment (Volume, Value and Sales Price)
5.1 China Familial Adenomatous Polyposis Treatment Sales and Value ()
5.1.1 China Familial Adenomatous Polyposis Treatment Sales and Growth Rate ()
5.1.2 China Familial Adenomatous Polyposis Treatment Revenue and Growth Rate ()
5.1.3 China Familial Adenomatous Polyposis Treatment Sales Price Trend ()
5.2 China Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Players ()
5.3 China Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Type ()
5.4 China Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Application ()
6 Japan Familial Adenomatous Polyposis Treatment (Volume, Value and Sales Price)
6.1 Japan Familial Adenomatous Polyposis Treatment Sales and Value ()
6.1.1 Japan Familial Adenomatous Polyposis Treatment Sales and Growth Rate ()
6.1.2 Japan Familial Adenomatous Polyposis Treatment Revenue and Growth Rate ()
6.1.3 Japan Familial Adenomatous Polyposis Treatment Sales Price Trend ()
6.2 Japan Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Players ()
6.3 Japan Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Type ()
6.4 Japan Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Application ()
7 Southeast Asia Familial Adenomatous Polyposis Treatment (Volume, Value and Sales Price)
7.1 Southeast Asia Familial Adenomatous Polyposis Treatment Sales and Value ()
7.1.1 Southeast Asia Familial Adenomatous Polyposis Treatment Sales and Growth Rate ()
7.1.2 Southeast Asia Familial Adenomatous Polyposis Treatment Revenue and Growth Rate ()
7.1.3 Southeast Asia Familial Adenomatous Polyposis Treatment Sales Price Trend ()
7.2 Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Players ()
7.3 Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Type ()
7.4 Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Application ()
8 India Familial Adenomatous Polyposis Treatment (Volume, Value and Sales Price)
8.1 India Familial Adenomatous Polyposis Treatment Sales and Value ()
8.1.1 India Familial Adenomatous Polyposis Treatment Sales and Growth Rate ()
8.1.2 India Familial Adenomatous Polyposis Treatment Revenue and Growth Rate ()
8.1.3 India Familial Adenomatous Polyposis Treatment Sales Price Trend ()
8.2 India Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Players ()
8.3 India Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Type ()
8.4 India Familial Adenomatous Polyposis Treatment Sales Volume and Market Share by Application ()
9 Global Familial Adenomatous Polyposis Treatment Players/Suppliers Profiles and Sales Data
9.1 Cancer Prevention Pharmaceuticals Inc
9.1.1 Company Basic Information, Manufacturing Base and Competitors
9.1.2 Familial Adenomatous Polyposis Treatment Product Category, Application and Specification
9.1.2.1 Product A
9.1.2.2 Product B
9.1.3 Cancer Prevention Pharmaceuticals Inc Familial Adenomatous Polyposis Treatment Sales, Revenue, Price and Gross Margin ()
9.1.4 Main Business/Business Overview
9.2 Marina Biotech Inc
9.2.1 Company Basic Information, Manufacturing Base and Competitors
9.2.2 Familial Adenomatous Polyposis Treatment Product Category, Application and Specification
9.2.2.1 Product A
9.2.2.2 Product B
9.2.3 Marina Biotech Inc Familial Adenomatous Polyposis Treatment Sales, Revenue, Price and Gross Margin ()
9.2.4 Main Business/Business Overview
9.3 Thetis Pharmaceuticals LLC
9.3.1 Company Basic Information, Manufacturing Base and Competitors
9.3.2 Familial Adenomatous Polyposis Treatment Product Category, Application and Specification
9.3.2.1 Product A
9.3.2.2 Product B
9.3.3 Thetis Pharmaceuticals LLC Familial Adenomatous Polyposis Treatment Sales, Revenue, Price and Gross Margin ()
9.3.4 Main Business/Business Overview
...
10 Familial Adenomatous Polyposis Treatment Maufacturing Cost Analysis
10.1 Familial Adenomatous Polyposis Treatment Key Raw Materials Analysis
10.1.1 Key Raw Materials
10.1.2 Price Trend of Key Raw Materials
10.1.3 Key Suppliers of Raw Materials
10.1.4 Market Concentration Rate of Raw Materials
10.2 Proportion of Manufacturing Cost Structure
10.2.1 Raw Materials
10.2.2 Labor Cost
10.2.3 Manufacturing Process Analysis of Familial Adenomatous Polyposis Treatment
10.3 Manufacturing Process Analysis of Familial Adenomatous Polyposis Treatment
11 Industrial Chain, Sourcing Strategy and Downstream Buyers
11.1 Familial Adenomatous Polyposis Treatment Industrial Chain Analysis
11.2 Upstream Raw Materials Sourcing
11.3 Raw Materials Sources of Familial Adenomatous Polyposis Treatment Major Manufacturers in
11.4 Downstream Buyers
12 Marketing Strategy Analysis, Distributors/Traders
12.1 Marketing Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.1.3 Marketing Channel Development Trend
12.2 Market Positioning
12.2.1 Pricing Strategy
12.2.2 Brand Strategy
12.2.3 Target Client
12.3 Distributors/Traders List
13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes Threat
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs/Customer Preference Change
13.3 Economic/Political Environmental Change
14 Global Familial Adenomatous Polyposis Treatment Market Forecast (2018-2025)
14.1 Global Familial Adenomatous Polyposis Treatment Sales Volume, Revenue and Price Forecast (2018-2025)
14.1.1 Global Familial Adenomatous Polyposis Treatment Sales Volume and Growth Rate Forecast (2018-2025)
14.1.2 Global Familial Adenomatous Polyposis Treatment Revenue and Growth Rate Forecast (2018-2025)
14.1.3 Global Familial Adenomatous Polyposis Treatment Price and Trend Forecast (2018-2025)
14.2 Global Familial Adenomatous Polyposis Treatment Sales Volume, Revenue and Growth Rate Forecast by Region (2018-2025)
14.2.1 Global Familial Adenomatous Polyposis Treatment Sales Volume and Growth Rate Forecast by Regions (2018-2025)
14.2.2 Global Familial Adenomatous Polyposis Treatment Revenue and Growth Rate Forecast by Regions (2018-2025)
14.2.3 United States Familial Adenomatous Polyposis Treatment Sales Volume, Revenue and Growth Rate Forecast (2018-2025)
14.2.4 Europe Familial Adenomatous Polyposis Treatment Sales Volume, Revenue and Growth Rate Forecast (2018-2025)
14.2.5 China Familial Adenomatous Polyposis Treatment Sales Volume, Revenue and Growth Rate Forecast (2018-2025)
14.2.6 Japan Familial Adenomatous Polyposis Treatment Sales Volume, Revenue and Growth Rate Forecast (2018-2025)
14.2.7 Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume, Revenue and Growth Rate Forecast (2018-2025)
14.2.8 India Familial Adenomatous Polyposis Treatment Sales Volume, Revenue and Growth Rate Forecast (2018-2025)
14.3 Global Familial Adenomatous Polyposis Treatment Sales Volume, Revenue and Price Forecast by Type (2018-2025)
14.3.1 Global Familial Adenomatous Polyposis Treatment Sales Forecast by Type (2018-2025)
14.3.2 Global Familial Adenomatous Polyposis Treatment Revenue Forecast by Type (2018-2025)
14.3.3 Global Familial Adenomatous Polyposis Treatment Price Forecast by Type (2018-2025)
14.4 Global Familial Adenomatous Polyposis Treatment Sales Volume Forecast by Application (2018-2025)
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Disclaimer
List of Tables and Figures
Figure Product Picture of Familial Adenomatous Polyposis Treatment
Figure Global Familial Adenomatous Polyposis Treatment Sales Volume Comparison (K Pcs) by Type
Figure Global Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type (Product Category) in
Figure Icosapent Product Picture
Figure Eflornithine Hydrochloride Product Picture
Figure Aspirin Product Picture
Figure CEQ-508 Product Picture
Figure Others Product Picture
Figure Global Familial Adenomatous Polyposis Treatment Sales Comparison (K Pcs) by Application
Figure Global Sales Market Share of Familial Adenomatous Polyposis Treatment by Application in
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Others Examples
Table Key Downstream Customer in Others
Figure Global Familial Adenomatous Polyposis Treatment Market Size (Million USD) by Regions
Figure United States Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate
Figure Europe Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate
Figure China Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate
Figure Japan Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate
Figure Southeast Asia Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate
Figure India Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate
Figure Global Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) and Growth Rate
Figure Global Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate
Figure Global Market Major Players Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) ()
Table Global Familial Adenomatous Polyposis Treatment Sales (K Pcs) of Key Players/Suppliers ()
Table Global Familial Adenomatous Polyposis Treatment Sales Share by Players/Suppliers ()
Figure Familial Adenomatous Polyposis Treatment Sales Share by Players/Suppliers
Figure Familial Adenomatous Polyposis Treatment Sales Share by Players/Suppliers
Figure Global Familial Adenomatous Polyposis Treatment Revenue (Million USD) by Players/Suppliers ()
Table Global Familial Adenomatous Polyposis Treatment Revenue (Million USD) by Players/Suppliers ()
Table Global Familial Adenomatous Polyposis Treatment Revenue Share by Players/Suppliers ()
Table Global Familial Adenomatous Polyposis Treatment Revenue Share by Players
Table Global Familial Adenomatous Polyposis Treatment Revenue Share by Players
Table Global Familial Adenomatous Polyposis Treatment Sales (K Pcs) and Market Share by Type ()
Table Global Familial Adenomatous Polyposis Treatment Sales Share (K Pcs) by Type ()
Figure Sales Market Share of Familial Adenomatous Polyposis Treatment by Type ()
Figure Global Familial Adenomatous Polyposis Treatment Sales Growth Rate by Type ()
Table Global Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Market Share by Type ()
Table Global Familial Adenomatous Polyposis Treatment Revenue Share by Type ()
Figure Revenue Market Share of Familial Adenomatous Polyposis Treatment by Type ()
Figure Global Familial Adenomatous Polyposis Treatment Revenue Growth Rate by Type ()
Table Global Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) and Market Share by Region ()
Table Global Familial Adenomatous Polyposis Treatment Sales Share by Region ()
Figure Sales Market Share of Familial Adenomatous Polyposis Treatment by Region ()
Figure Global Familial Adenomatous Polyposis Treatment Sales Growth Rate by Region in
Table Global Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Market Share by Region ()
Table Global Familial Adenomatous Polyposis Treatment Revenue Share (%) by Region ()
Figure Revenue Market Share of Familial Adenomatous Polyposis Treatment by Region ()
Figure Global Familial Adenomatous Polyposis Treatment Revenue Growth Rate by Region in
Table Global Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Market Share by Region ()
Table Global Familial Adenomatous Polyposis Treatment Revenue Share (%) by Region ()
Figure Revenue Market Share of Familial Adenomatous Polyposis Treatment by Region ()
Figure Global Familial Adenomatous Polyposis Treatment Revenue Market Share by Region in
Table Global Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) and Market Share by Application ()
Table Global Familial Adenomatous Polyposis Treatment Sales Share (%) by Application ()
Figure Sales Market Share of Familial Adenomatous Polyposis Treatment by Application ()
Figure Global Familial Adenomatous Polyposis Treatment Sales Market Share by Application ()
Figure United States Familial Adenomatous Polyposis Treatment Sales (K Pcs) and Growth Rate ()
Figure United States Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate ()
Figure United States Familial Adenomatous Polyposis Treatment Sales Price (USD/Pcs) Trend ()
Table United States Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Players ()
Table United States Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Players ()
Figure United States Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Players in
Table United States Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Type ()
Table United States Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type ()
Figure United States Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type in
Table United States Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Application ()
Table United States Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Application ()
Figure United States Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Application in
Figure Europe Familial Adenomatous Polyposis Treatment Sales (K Pcs) and Growth Rate ()
Figure Europe Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate ()
Figure Europe Familial Adenomatous Polyposis Treatment Sales Price (USD/Pcs) Trend ()
Table Europe Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Players ()
Table Europe Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Players ()
Figure Europe Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Players in
Table Europe Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Type ()
Table Europe Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type ()
Figure Europe Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type in
Table Europe Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Application ()
Table Europe Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Application ()
Figure Europe Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Application in
Figure China Familial Adenomatous Polyposis Treatment Sales (K Pcs) and Growth Rate ()
Figure China Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate ()
Figure China Familial Adenomatous Polyposis Treatment Sales Price (USD/Pcs) Trend ()
Table China Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Players ()
Table China Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Players ()
Figure China Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Players in
Table China Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Type ()
Table China Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type ()
Figure China Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type in
Table China Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Application ()
Table China Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Application ()
Figure China Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Application in
Figure Japan Familial Adenomatous Polyposis Treatment Sales (K Pcs) and Growth Rate ()
Figure Japan Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate ()
Figure Japan Familial Adenomatous Polyposis Treatment Sales Price (USD/Pcs) Trend ()
Table Japan Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Players ()
Table Japan Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Players ()
Figure Japan Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Players in
Table Japan Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Type ()
Table Japan Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type ()
Figure Japan Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type in
Table Japan Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Application ()
Table Japan Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Application ()
Figure Japan Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Application in
Figure Southeast Asia Familial Adenomatous Polyposis Treatment Sales (K Pcs) and Growth Rate ()
Figure Southeast Asia Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate ()
Figure Southeast Asia Familial Adenomatous Polyposis Treatment Sales Price (USD/Pcs) Trend ()
Table Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Players ()
Table Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Players ()
Figure Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Players in
Table Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Type ()
Table Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type ()
Figure Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type in
Table Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Application ()
Table Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Application ()
Figure Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Application in
Figure India Familial Adenomatous Polyposis Treatment Sales (K Pcs) and Growth Rate ()
Figure India Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate ()
Figure India Familial Adenomatous Polyposis Treatment Sales Price (USD/Pcs) Trend ()
Table India Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Players ()
Table India Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Players ()
Figure India Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Players in
Table India Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Type ()
Table India Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type ()
Figure India Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Type in
Table India Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) by Application ()
Table India Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Application ()
Figure India Familial Adenomatous Polyposis Treatment Sales Volume Market Share by Application in
Table Cancer Prevention Pharmaceuticals Inc Basic Information List
Table Cancer Prevention Pharmaceuticals Inc Familial Adenomatous Polyposis Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin ()
Figure Cancer Prevention Pharmaceuticals Inc Familial Adenomatous Polyposis Treatment Sales Growth Rate ()
Figure Cancer Prevention Pharmaceuticals Inc Familial Adenomatous Polyposis Treatment Sales Global Market Share ()
Figure Cancer Prevention Pharmaceuticals Inc Familial Adenomatous Polyposis Treatment Revenue Global Market Share ()
Table Marina Biotech Inc Basic Information List
Table Marina Biotech Inc Familial Adenomatous Polyposis Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin ()
Figure Marina Biotech Inc Familial Adenomatous Polyposis Treatment Sales Growth Rate ()
Figure Marina Biotech Inc Familial Adenomatous Polyposis Treatment Sales Global Market Share ()
Figure Marina Biotech Inc Familial Adenomatous Polyposis Treatment Revenue Global Market Share ()
Table Thetis Pharmaceuticals LLC Basic Information List
Table Thetis Pharmaceuticals LLC Familial Adenomatous Polyposis Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin ()
Figure Thetis Pharmaceuticals LLC Familial Adenomatous Polyposis Treatment Sales Growth Rate ()
Figure Thetis Pharmaceuticals LLC Familial Adenomatous Polyposis Treatment Sales Global Market Share (
Figure Thetis Pharmaceuticals LLC Familial Adenomatous Polyposis Treatment Revenue Global Market Share ()
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Familial Adenomatous Polyposis Treatment
Figure Manufacturing Process Analysis of Familial Adenomatous Polyposis Treatment
Figure Familial Adenomatous Polyposis Treatment Industrial Chain Analysis
Table Raw Materials Sources of Familial Adenomatous Polyposis Treatment Major Players in
Table Major Buyers of Familial Adenomatous Polyposis Treatment
Table Distributors/Traders List
Figure Global Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Global Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure Global Familial Adenomatous Polyposis Treatment Price (USD/Pcs) and Trend Forecast (2018-2025)
Table Global Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) Forecast by Regions (2018-2025)
Figure Global Familial Adenomatous Polyposis Treatment Sales Volume Market Share Forecast by Regions (2018-2025)
Figure Global Familial Adenomatous Polyposis Treatment Sales Volume Market Share Forecast by Regions in 2025
Table Global Familial Adenomatous Polyposis Treatment Revenue (Million USD) Forecast by Regions (2018-2025)
Figure Global Familial Adenomatous Polyposis Treatment Revenue Market Share Forecast by Regions (2018-2025)
Figure Global Familial Adenomatous Polyposis Treatment Revenue Market Share Forecast by Regions in 2025
Figure United States Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure United States Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure Europe Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Europe Familial Adenomatous Polyposis Treatment Revenue and Growth Rate Forecast (2018-2025)
Figure China Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure China Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure Japan Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Japan Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure Southeast Asia Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Southeast Asia Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure India Familial Adenomatous Polyposis Treatment Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure India Familial Adenomatous Polyposis Treatment Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Table Global Familial Adenomatous Polyposis Treatment Sales (K Pcs) Forecast by Type (2018-2025)
Figure Global Familial Adenomatous Polyposis Treatment Sales Volume Market Share Forecast by Type (2018-2025)
Table Global Familial Adenomatous Polyposis Treatment Revenue (Million USD) Forecast by Type (2018-2025)
Figure Global Familial Adenomatous Polyposis Treatment Revenue Market Share Forecast by Type (2018-2025)
Table Global Familial Adenomatous Polyposis Treatment Price (USD/Pcs) Forecast by Type (2018-2025)
Table Global Familial Adenomatous Polyposis Treatment Sales (K Pcs) Forecast by Application (2018-2025)
Figure Global Familial Adenomatous Polyposis Treatment Sales Market Share Forecast by Application (2018-2025)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
1. Segments Analysis
By Treatment Modality & Approach:
-
Surgical Intervention (Current Standard of Care):
-
Prophylactic Colectomy: Total or subtotal colectomy, often with ileorectal anastomosis (IRA) or restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). This is the definitive, curative-intent procedure but carries significant morbidity and quality-of-life impacts.
-
Endoscopic Polypectomy: For management of duodenal/ampullary polyps or rectal stump surveillance post-colectomy.
-
-
Chemopreventive Pharmacotherapy (Key Growth Segment):
-
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Established off-label use (e.g., Sulindac, Celecoxib). Act as the historical benchmark for polyp regression but are limited by cardiovascular/renal side effects and lack of FDA approval for FAP.
-
Novel, Targeted Chemoprevention Agents: The focus of clinical development. Includes:
-
Eflornithine + Sulindac Combination (CPP-1X/sul): A leading investigational combination with Phase III data showing significant efficacy in delaying disease progression.
-
Other Novel Mechanisms: Agents targeting Wnt/β-catenin pathway (dysregulated in FAP), COX-2 inhibitors, and other molecular targets.
-
-
-
Supportive & Symptomatic Care: Includes nutritional support, pain management, and treatment of extra-colonic manifestations (desmoid tumors, osteomas, CHRPE).
By Patient Population & Disease Stage:
-
At-Risk & Pre-Prophylactic Colectomy Patients: The primary target for chemoprevention to delay or avoid surgery.
-
Post-Colectomy Patients (with IRA): Patients with retained rectum requiring lifelong surveillance and management of rectal polyps. A key population for chemoprevention to prevent proctectomy.
-
Patients with Desmoid Tumors (Aggressive Fibromatosis): A severe extra-colonic manifestation requiring specialized treatment (e.g., tyrosine kinase inhibitors, chemotherapy).
By Distribution Channel:
-
Hospital Pharmacies (Specialty Dispensing): For inpatient surgical care and infusion therapies.
-
Specialty Pharmacies & Mail-Order: For dispensing high-cost, orphan-designated oral chemopreventive drugs.
-
Retail Pharmacies: For generic NSAIDs and supportive medications.
2. Key Players
The market involves innovative biotechnology firms, specialty pharma, and large pharma with orphan/oncology divisions. Surgical care is decentralized.
Leading Companies (Therapeutics Focus):
-
Cancer Prevention Pharmaceuticals, Inc. (CPP) - (Lead asset: Eflornithine + Sulindac [CPP-1X/sul])
-
Pfizer Inc. - (Historical role with Celebrex®/celecoxib; interest in oncology)
-
Ionis Pharmaceuticals, Inc. - (Antisense oligonucleotide platform for rare diseases)
-
Thetis Pharmaceuticals LLC - (TPI-2154, a novel chemoprevention agent)
-
Recursion Pharmaceuticals - (AI-driven drug discovery for rare diseases like FAP)
-
SpringWorks Therapeutics, Inc. - (Focus on rare tumors, including desmoid tumors common in FAP)
-
Deciphera Pharmaceuticals, Inc. - (QINLOCK®/ripretinib for desmoid tumors)
-
Bayer AG - (Nexavar®/sorafenib used off-label for desmoid tumors)
-
F. Hoffmann-La Roche Ltd - (Through its oncology and diagnostics divisions)
-
Guardant Health, Inc. - (Liquid biopsy for monitoring and early detection in high-risk patients)
